Hyderabad-based Natco Pharma, best known for challenging drug patents in India, has filed 11 applications with the U.S. FDA to market generic drugs before their U.S. patents expire.
Natco, looking to be among the first to win approval for its generic version of Teva's Copaxone, is also looking to market generics for big-ticket drugs such as Celgene Corp.’s Revlimid for bone cancer and Roche’s Tamiflu.
Currently, Natco derives only a seventh of its annual revenue from U.S. drug sales. According to the company, their new goal is to file eight to 10 generic drug applications per year in the U.S.
Read the Bloomberg article